Application of MET targeted nanoparticle in visual assessment of head and neck squamous cell carcinoma

A clinical trial to evaluate the effectiveness of a topical applicated MET targeted probe for fluorescence imaging of oral lesions

Status

Recruiting

Phases

Early Phase 1

Study type

Observational

Source

ChiCTR

Registry ID

ChiCTR2200058058

Enrollment

Unknown

Registered

2022-03-28

Start date

2021-05-01

Completion date

Unknown

Last updated

2023-12-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Oral squamous cell carcinoma

Interventions

Gold Standard:Results of pathological paraffin section diagnosis

Index test:Imaging data of topical application of MET targeted probes with high definition near infrared fluorescence

Eligibility

Sex/Gender

All

Age

18 Years to 80 Years

Inclusion criteria

Inclusion criteria: 1. Patients aged 18-80 years; 2. Patients with oral squamous cell carcinoma suspected by clinical and conventional imaging diagnosis and indications of surgery; 3. Patients voluntarily participated in the clinical trial and signed informed consent.

Exclusion criteria

Exclusion criteria: 1. Have received surgery for oral lesions; 2. Have received radiotherapy or neoadjuvant chemotherapy for oral squamous cell carcinoma; 3. ICG, iodine allergy (including allergic reaction test allergy); 4. The investigator did not consider it suitable to participate in this clinical trial.

Design outcomes

Primary

Measure	Time frame
Fluorescenceintensity;MET expression area fraction;	—

Secondary

Measure	Time frame
Tumor grade;	—

Countries

China

Contacts

Public ContactTao Xiaofeng

Shanghai Ninth People's Hospital, Shanghai Jiao Tong Univesity School of Medicine

cjr.taoxiaofeng@vip.163.com+86 13801666309

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026